Skip to content
TrackPodcasts
healthApr 22, 202250:03pending

Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia

About this episode

In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data surprises us, and makes us question our own practices!

Get every episode summarized

Each time WolverHeme Happy Hour publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia

WolverHeme Happy Hour

0:00
50:03

More episodes

More from WolverHeme Happy Hour

View all episodes →